Framingham, MA — SCIEX, a global leader in life science analytical technologies, announced that Dr. Subhasish "Babu" Purkayastha, Director, R&D at SCIEX, has been awarded the Human Proteome Organization (HUPO) Science and Technology Award for efforts in commercialization of isobaric labeling for protein quantification with the development of iTRAQ chemistries. The award further establishes SCIEX as an innovator in proteomics research as Dr. Purkayastha is the second SCIEX team member to be recognized by HUPO in the past two years. In 2013, Dr. Christie Hunter received the award for her contributions to the development and commercialization of a breakthrough approach for targeted proteomics. Dr. Purkayastha will be presented his award for his contribution to advancing proteomics at this year’s HUPO 2014 conference in Madrid.
The HUPO Science and Technology Award is presented for efforts to commercialize a technology, product or procedure, which makes the life of the proteomics researcher easier. Dr. Purkayastha has been a leader in enabling protein expression analysis, quantitation, and multiplexing by mass spectrometry. A key figure in the commercialization of breakthrough technologies such as ICAT, cleavable ICAT, and iTRAQ (both 4-plex and 8-plex), all of which have enjoyed wide use, with over 1,000 publications, and acceptance in proteomics laboratories worldwide, Dr. Purkayastha has played a crucial role leading a collective vision bringing multiplexing to the market.
"Our team of chemists, software developers, MS application scientists and our partners are the reason we were able to commercialize the first multiplex solution in 2004 so customers could recognize the benefits of multiplexing," said Dr. Babu Purkayastha, Director of Reagent R&D at SCIEX. "We made it easy for scientists to adopt the technology and focus their research on advancing the knowledge of biology with more relevant data and consistent results. Our goal is to provide tools that help our customers to design and perform studies that address key biological questions such as identifying biomarkers that goes a long way in developing treatments and tests for diseases such as Alzheimer’s, Sepsis, and Cancer, among others."
"SCIEX would like to congratulate Dr. Babu Purkayastha for receiving such a prestigious award from HUPO in recognition to his commitment and advancement to proteomics research with the development of iTRAQ," said Veronique Berger, V.P. Marketing for SCIEX. We are honored to be associated with two of the most forward-thinking researchers in the proteomics industry in Dr. Purkayastha and Dr. Christie Hunter, HUPO’s 2013 recipient. ‘Answers for Science. Knowledge for Life.TM’ is about investing in innovative solutions that impact the proteomics industry so scientists can do what they do best, make a difference."
Throughout the week at the HUPO WW congress in Madrid SCIEX will continue showcasing new innovations for Proteomics such as the HUPO announced OneOmics project, an exclusive partnership to bring together SWATH™ acquisition software based next-generation proteomics (NGP) and next-generation sequencing (NGS) tools in a cloud computing environment. As well as the ASMS launched Next-generation Proteomics Platform including the new TripleTOF® 6600 system with SWATH™ 2.0 technology. In addition, scientists from the company will be demonstrating ways to accelerate and improve workflows on a variety of instruments.
Follow SCIEX at HUPO on Twitter with hashtag #ABSCIEXWORLD and #hupo2014.
Illumina is transforming human health as the global leader in sequencing and array-based technologies. The company serves customers in a broad range of markets, enabling the universal adoption of genomic solutions in research and clinical settings.
Illumina Forward-Looking Statements
This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.